Incyte (INCY) Competitors $62.66 +2.23 (+3.69%) Closing price 04/30/2025 04:00 PM EasternExtended Trading$59.50 -3.16 (-5.04%) As of 07:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock INCY vs. ALNY, BIIB, UTHR, BMRN, NBIX, EXEL, EXAS, RGEN, HALO, and MDGLShould you be buying Incyte stock or one of its competitors? The main competitors of Incyte include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), Exelixis (EXEL), Exact Sciences (EXAS), Repligen (RGEN), Halozyme Therapeutics (HALO), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "biotechnology" industry. Incyte vs. Alnylam Pharmaceuticals Biogen United Therapeutics BioMarin Pharmaceutical Neurocrine Biosciences Exelixis Exact Sciences Repligen Halozyme Therapeutics Madrigal Pharmaceuticals Incyte (NASDAQ:INCY) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, community ranking, risk, earnings and dividends. Which has more risk & volatility, INCY or ALNY? Incyte has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 0.3, suggesting that its share price is 70% less volatile than the S&P 500. Is INCY or ALNY more profitable? Incyte has a net margin of 0.77% compared to Alnylam Pharmaceuticals' net margin of -12.37%. Incyte's return on equity of 0.05% beat Alnylam Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Incyte0.77% 0.05% 0.04% Alnylam Pharmaceuticals -12.37%N/A -6.83% Does the MarketBeat Community prefer INCY or ALNY? Incyte received 62 more outperform votes than Alnylam Pharmaceuticals when rated by MarketBeat users. However, 76.28% of users gave Alnylam Pharmaceuticals an outperform vote while only 72.20% of users gave Incyte an outperform vote. CompanyUnderperformOutperformIncyteOutperform Votes122672.20% Underperform Votes47227.80% Alnylam PharmaceuticalsOutperform Votes116476.28% Underperform Votes36223.72% Do insiders & institutionals have more ownership in INCY or ALNY? 97.0% of Incyte shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 17.6% of Incyte shares are owned by insiders. Comparatively, 1.5% of Alnylam Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts prefer INCY or ALNY? Incyte presently has a consensus price target of $73.94, suggesting a potential upside of 18.00%. Alnylam Pharmaceuticals has a consensus price target of $315.58, suggesting a potential upside of 19.88%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than Incyte.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Incyte 1 Sell rating(s) 13 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.21Alnylam Pharmaceuticals 1 Sell rating(s) 4 Hold rating(s) 21 Buy rating(s) 0 Strong Buy rating(s) 2.77 Which has higher valuation & earnings, INCY or ALNY? Incyte has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIncyte$4.24B2.86$32.62M$0.27232.07Alnylam Pharmaceuticals$2.25B15.23-$278.16M-$2.17-121.31 Does the media prefer INCY or ALNY? In the previous week, Incyte had 15 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 40 mentions for Incyte and 25 mentions for Alnylam Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 1.02 beat Incyte's score of 0.85 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incyte 20 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 4 Negative mention(s) 2 Very Negative mention(s) Positive Alnylam Pharmaceuticals 17 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive SummaryIncyte beats Alnylam Pharmaceuticals on 12 of the 18 factors compared between the two stocks. Get Incyte News Delivered to You Automatically Sign up to receive the latest news and ratings for INCY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INCY vs. The Competition Export to ExcelMetricIncyteCommercial physical research IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.13B$3.09B$5.57B$7.83BDividend YieldN/A2.70%5.11%4.22%P/E Ratio232.0891.1522.4218.48Price / Sales2.86142.73394.10103.91Price / Cash128.9434.5738.1834.62Price / Book3.522.406.774.25Net Income$32.62M$113.28M$3.22B$248.23M7 Day Performance8.03%1.88%3.25%3.29%1 Month Performance3.40%24.00%0.01%2.42%1 Year Performance20.38%-1.03%18.00%5.54% Incyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INCYIncyte4.7048 of 5 stars$62.66+3.7%$73.53+17.4%+20.4%$12.13B$4.24B232.082,320Earnings ReportAnalyst ForecastALNYAlnylam Pharmaceuticals4.319 of 5 stars$232.75-0.8%$315.58+35.6%+82.9%$30.28B$2.25B-107.262,000Analyst DowngradePositive NewsBIIBBiogen4.6878 of 5 stars$116.49-1.8%$213.15+83.0%-43.6%$17.05B$9.68B10.418,720Analyst DowngradeAnalyst RevisionUTHRUnited Therapeutics4.9094 of 5 stars$284.25-0.2%$395.67+39.2%+29.3%$12.77B$2.88B12.48980Earnings ReportAnalyst RevisionNews CoveragePositive NewsGap UpBMRNBioMarin Pharmaceutical4.9257 of 5 stars$58.65-0.9%$94.00+60.3%-21.1%$11.19B$2.85B26.663,080Positive NewsNBIXNeurocrine Biosciences4.8698 of 5 stars$100.68-0.7%$161.86+60.8%-21.7%$9.96B$2.36B30.601,200Analyst ForecastAnalyst RevisionEXELExelixis4.0784 of 5 stars$35.59-1.7%$37.59+5.6%+66.9%$9.96B$2.17B20.111,220Short Interest ↑Analyst RevisionPositive NewsEXASExact Sciences4.4826 of 5 stars$43.10+3.7%$69.25+60.7%-23.1%$8.01B$2.76B-7.746,400Positive NewsRGENRepligen4.8598 of 5 stars$131.64+1.3%$176.82+34.3%-16.0%$7.39B$634.44M-258.122,020Earnings ReportAnalyst UpgradeAnalyst RevisionNews CoveragePositive NewsHALOHalozyme Therapeutics3.9987 of 5 stars$57.29-2.6%$62.89+9.8%+61.2%$7.08B$1.02B16.70390Upcoming EarningsInsider TradeAnalyst RevisionMDGLMadrigal Pharmaceuticals3.7383 of 5 stars$295.02-2.2%$378.44+28.3%+63.7%$6.51B$180.13M-11.7690News CoveragePositive NewsGap Down Related Companies and Tools Related Companies Alnylam Pharmaceuticals Competitors Biogen Competitors United Therapeutics Competitors BioMarin Pharmaceutical Competitors Neurocrine Biosciences Competitors Exelixis Competitors Exact Sciences Competitors Repligen Competitors Halozyme Therapeutics Competitors Madrigal Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INCY) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Incyte Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Incyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy INCY Stock Free INCY Stock Alerts